A Study of Three Treatment Combinations Using Zidovudine Plus Lamivudine Plus Indinavir in HIV-Infected Patients
Status:
Completed
Trial end date:
1997-12-01
Target enrollment:
Participant gender:
Summary
To compare the proportion of patients who sustain suppression of plasma HIV RNA to
undetectable levels [AS PER AMENDMENT 09/19/97: below 200 copies/mL by Roche UltraSensitive
assay] among the 3 regimens during the maintenance phase.
The objective of antiretroviral therapy is to reduce HIV replication, preserve immunologic
function and delay the development of HIV-related complications. In patients administered
potent antiretroviral regimens, HIV RNA levels are reduced below 500 copies/ml of plasma and
below the level of detection of commercially available assays. This protocol attempts to
learn if a less intensive regimen can successfully sustain viral suppression after induction
with a triple-drug regimen. The study also addresses whether HIV can be eradicated in
patients following prolonged treatment with induction and maintenance regimens.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)